Similar articles for PMID: 19952301

Year	Number of Results
2004	1
2006	4
2007	3
2008	7
2009	15
2010	16
2011	15
2012	19
2013	12
2014	17
2015	4
2016	5
2017	4
2018	2
2020	2
2022	3
2023	0

1

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.

Davidson JA. Davidson JA. Cleve Clin J Med. 2009 Dec;76 Suppl 5:S28-38. doi: 10.3949/ccjm.76.s5.05. Cleve Clin J Med. 2009. PMID: 19952301 Free article. Review.

2

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Tasyurek HM, et al. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Diabetes Metab Res Rev. 2014. PMID: 24989141 Review.

3

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. Madsbad S, et al. Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Diabetes Obes Metab. 2011. PMID: 21208359 Review.

4

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J. Morales J. Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Postgrad Med. 2011. PMID: 22104467

5

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.

6

Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.

Garber AJ. Garber AJ. Am J Manag Care. 2010 Aug;16(7 Suppl):S187-94. Am J Manag Care. 2010. PMID: 20809667 Free article. Review.

7

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N. Mikhail N. Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845. Expert Opin Investig Drugs. 2008. PMID: 18491986 Review.

8

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.

9

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ. Verspohl EJ. Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Pharmacol Ther. 2009. PMID: 19545590 Review.

10

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed